Analyst Price Target is GBX 498.75
▲ +122.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 498.75, with a high forecast of GBX 1,010 and a low forecast of GBX 180. The average price target represents a 122.66% upside from the last price of GBX 224.
Current Consensus is
Hold
The current consensus among 4 polled investment analysts is to hold stock in Oxford Biomedica. This Hold consensus rating has held steady for over two years.
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Read More
